(Q39472057)

12 September 2017

title

Ontak reduces the immunosuppressive tumor environment and enhances successful therapeutic vaccination in HER-2/neu-tolerant mice (English)

1 reference

12 September 2017

Angelos D Gritzapis

1

1 reference

12 September 2017

Ioannis F Voutsas

series ordinal

2

1 reference

12 September 2017

Constantin N Baxevanis

series ordinal

3

1 reference

12 September 2017

publication date

18 September 2011

1 reference

Cancer Immunology, Immunotherapy

12 September 2017

published in

1 reference

12 September 2017

volume

61

1 reference

12 September 2017

issue

3

1 reference

12 September 2017

page(s)

397-407

1 reference

Human cd25(+)cd4(+) t regulatory cells suppress naive and memory T cell proliferation and can be expanded in vitro without loss of function.

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Certified professionals: CD4(+)CD25(+) suppressor T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

CD4(+) regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Immunoregulatory T cells in tumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Escape from immunotherapy: possible mechanisms that influence tumor regression/progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Regulation of tumour immunity by CD25+ T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Denileukin diftitox: a concise clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Peptide vaccination breaks tolerance to HER-2/neu by generating vaccine-specific FasL(+) CD4(+) T cells: first evidence for intratumor apoptotic regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Identification of a novel immunogenic HLA-A*0201-binding epitope of HER-2/neu with potent antitumor properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Vaccination with human HER-2/neu (435-443) CTL peptide induces effective antitumor immunity against HER-2/neu-expressing tumor cells in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Induction of potent CD4+ T cell-mediated antitumor responses by a helper HER-2/neu peptide linked to the Ii-Key moiety of the invariant chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Transient T cell depletion causes regression of melanoma metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Role of CD4+ cytotoxic T lymphocytes in the control of viral diseases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Tumor-Infiltrating FOXP3+ T Regulatory Cells Show Strong Prognostic Significance in Colorectal Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

Chemoimmunotherapy of Tumors: Cyclophosphamide Synergizes with Exosome Based Vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-011-1113-4

10.1007/S00262-011-1113-4

21 January 2018

Identifiers

DOI

1 reference

12 September 2017

1 reference